Protagonist Therapeutics Q3 net loss widens to $39.3 mln

Protagonist Therapeutics

06/11/2025 21:53

Overview

Protagonist Therapeutics reports Q3 net loss of $39.3 mln, increased R&D expenses noted

Cash reserves of $678.8 mln expected to sustain operations through 2028

NDA for icotrokinra submitted to FDA, rusfertide gets breakthrough designation

Outlook

Protagonist expects rusfertide NDA filing by end of 2025

Company anticipates PN-477sc clinical study initiation by mid-2026

Protagonist plans to nominate oral hepcidin candidate by year-end

Result Drivers

R&D EXPENSES - Increased by $4 mln from the prior year, primarily due to increases in drug discovery and pre-clinical research expenses

G&A EXPENSES - Increased by $1 mln primarily due to increases in professional services

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 License and Collaboration Revenue
$4.71 mln
Q3 EPS
-$0.62
Q3 Net Income
-$39.34 mln
Q3 Income from Operations
-$46.42 mln
Q3 Operating Expenses
$51.13 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $81.00, about 3.9% above its November 5 closing price of $77.88

Press Release: ID:nACSR1Tsma

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)